Advertisement

Topics

Sensei Biotherapeutics, Inc. Company Profile

23:03 EDT 24th September 2018 | BioPortfolio

Sensei Biotherapeutics is a privately-held biopharmaceutical company developing immuno-oncology therapies that stimulate the immune system to ‘teach’ it to recognize cancer-specific antigens and attack cancer cells. The company’s patented and proprietary technology platform, called SPIRIT, creates novel therapies that target neoantigens or altered self-antigens – which are antigens encoded by tumor-specific mutated genes – and are designed to overcome self-tolerance by eliciting a potent cellular and humoral immune response to eliminate cancer cells. Sensei’s precision medicine approach in immuno-oncology includes novel therapies along with companion diagnostics. The company’s lead drug candidate, SNS-301, is a first-in-class cancer vaccine that targets a novel embryonic self-antigen and has successfully completed a Phase 1 clinical study. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.


News Articles [246 Associated News Articles listed on BioPortfolio]

Panacea has new CEO to add to new name

Sensei Biotherapeutics, a privately-held company known as Panacea Pharmaceuticals until earlier this…

Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company developing immuno-oncology therapies that teach the immune system to recognize and attack cancer, today an...

Sensei Biotherapeutics Appoints John Celebi as President and Chief Executive Officer

Experienced Biotechnology Executive to Lead Company’s Growth Strategy for Cancer Immunotherapies, Including Lead Clinical Candidate SNS-301 Sensei Biotherapeutics, Inc., a p...

Sensei Biotherapeutics Reports New Data from Phase 1 Clinical Trial of SNS-301

SNS-301 demonstrated a strong safety profile and promising immune responses in patients with biochemically recurrent prostate cancer SNS-301 is a first-in-class immunothe...

Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion ...

www.wallstequities.com/registration Eleven Biotherapeutics On Wednesday, shares in Cambridge, Massachusetts-based Eleven Biotherapeutics Inc. recorded a trading volume of 1.09 million shares, whic...

Codexis Appoints Biotherapeutics R&D VP

Dr. Alaoui will be responsible for the biotherapeutics discovery pipeline and acceleration of drug candidates to the clinic

Cancer Research UK launches new research hub for biotherapeutics

Cancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment...Read More... The post Cancer Research UK launches new research hub fo...

Appointments: News From Sensei, DelMar, Seattle Genetics, Astellas, Galecto, Roivant Sciences And PDL BioPharma

This week's announcements include new CEOs at Sensei and DelMar, new chief medical officers at Seattle Genetics, Astellas Pharma, Galecto...   

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [27 Associated PubMed Articles listed on BioPortfolio]

SENSEI: First Direct-Detection Constraints on Sub-GeV Dark Matter from a Surface Run.

The Sub-Electron-Noise Skipper CCD Experimental Instrument (SENSEI) uses the recently developed Skipper-CCD technology to search for electron recoils from the interaction of sub-GeV dark matter partic...

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Integrated BioTherapeutics.

Live bacterial biotherapeutics in the clinic.

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [104 Associated Companies listed on BioPortfolio]

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics is a privately-held biopharmaceutical company developing immuno-oncology therapies that stimulate the immune system to ‘teach’ it to recognize can...

Sensei Labs

Rethinking the technology of management, Sensei Labs builds smarter, more intuitive workplace solutions to help rapidly growing companies execute and evolve faster in a way their ...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Hansen Medical

Hansen Medical develops and manufactures a new generation of medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. While ear...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "Sensei Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Sensei Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Sensei Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Sensei Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sensei Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Sensei Biotherapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record